BR112017021809A2 - avaliação de riscos associados com fármacos terapêuticos - Google Patents

avaliação de riscos associados com fármacos terapêuticos

Info

Publication number
BR112017021809A2
BR112017021809A2 BR112017021809A BR112017021809A BR112017021809A2 BR 112017021809 A2 BR112017021809 A2 BR 112017021809A2 BR 112017021809 A BR112017021809 A BR 112017021809A BR 112017021809 A BR112017021809 A BR 112017021809A BR 112017021809 A2 BR112017021809 A2 BR 112017021809A2
Authority
BR
Brazil
Prior art keywords
therapeutic drugs
therapeutic
patient
methods
selection
Prior art date
Application number
BR112017021809A
Other languages
English (en)
Inventor
D F S Barbosa Maria
Original Assignee
Conquerab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conquerab Inc filed Critical Conquerab Inc
Publication of BR112017021809A2 publication Critical patent/BR112017021809A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54391—Immunochromatographic test strips based on vertical flow
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B15/00—Systems controlled by a computer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F7/00—Methods or arrangements for processing data by operating upon the order or content of the data handled
    • G06F7/06—Arrangements for sorting, selecting, merging, or comparing data on individual record carriers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Automation & Control Theory (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

são fornecidos métodos para estimar a segurança e/ou eficácia de fármacos terapêuticos, que incluem dispositivos portáteis para o teste de anticorpos contra fármacos (acfs) e bancos de dados contendo dados anônimos de pacientes humanos e/ou animais e análises relacionadas. estes métodos e composições podem ser usados em várias aplicações, incluindo, mas não se limitando, ao seguinte: testes uniformes de acf em pacientes; seleção de fármaco terapêutico para tratamento do paciente; avaliação da necessidade de mudança de fármaco terapêutico ou aplicação de regimes de tolerância; seleção de pacientes para estudos clínicos; comparação de fármacos terapêuticos comercializados para uma dada doença e também terapia de gene; orientação científica para descobrir e/ou desenvolver fármacos terapêuticos; vigilância pós comercialização de fármacos terapêuticos.
BR112017021809A 2015-04-10 2016-04-06 avaliação de riscos associados com fármacos terapêuticos BR112017021809A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562146232P 2015-04-10 2015-04-10
US15/091,483 US9927443B2 (en) 2015-04-10 2016-04-05 Risk assessment for therapeutic drugs
PCT/US2016/026203 WO2016164452A1 (en) 2015-04-10 2016-04-06 Risk assessment for therapeutic drugs

Publications (1)

Publication Number Publication Date
BR112017021809A2 true BR112017021809A2 (pt) 2019-02-05

Family

ID=57072943

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021809A BR112017021809A2 (pt) 2015-04-10 2016-04-06 avaliação de riscos associados com fármacos terapêuticos

Country Status (6)

Country Link
US (1) US9927443B2 (pt)
EP (1) EP3280330A4 (pt)
AU (1) AU2016246578A1 (pt)
BR (1) BR112017021809A2 (pt)
CA (1) CA2982859C (pt)
WO (1) WO2016164452A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568567B1 (en) * 2016-05-31 2020-02-25 Vium, Inc Method of drug approval using motion vector analysis
EP3497444A4 (en) 2016-08-12 2020-11-11 Abreos Biosciences, Inc. DETECTION AND QUANTIFICATION OF NATALIZUMAB
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL286850A (pt) 1961-12-18 1900-01-01
US3811840A (en) 1969-04-01 1974-05-21 Miles Lab Test device for detecting low concentrations of substances in fluids
IT1006557B (it) 1971-09-08 1976-10-20 Bagshawe Kenneth Dawson Cella di reazione particolarmente utile in prove di radioimmunita
US4169138A (en) 1974-05-29 1979-09-25 Pharmacia Diagnostics Ab Method for the detection of antibodies
SE388694B (sv) 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
US4042335A (en) 1975-07-23 1977-08-16 Eastman Kodak Company Integral element for analysis of liquids
US4219335A (en) 1978-09-18 1980-08-26 E. I. Du Pont De Nemours And Company Immunochemical testing using tagged reagents
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
US4258001A (en) 1978-12-27 1981-03-24 Eastman Kodak Company Element, structure and method for the analysis or transport of liquids
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4654309A (en) 1980-12-19 1987-03-31 Minnesota Mining And Manufacturing Co. Test method and article for estimating the concentration of free acid in liquid
US4348207A (en) 1981-01-29 1982-09-07 Cooper Laboratories, Inc. Method and means for determination of pregnancy
US4446232A (en) 1981-10-13 1984-05-01 Liotta Lance A Enzyme immunoassay with two-zoned device having bound antigens
US4435504A (en) 1982-07-15 1984-03-06 Syva Company Immunochromatographic assay with support having bound "MIP" and second enzyme
US4503143A (en) 1982-08-20 1985-03-05 Btc Diagnostics Limited Partnership Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen
US4459358A (en) 1982-12-29 1984-07-10 Polaroid Corporation Multilayer element for analysis
US4537861A (en) 1983-02-03 1985-08-27 Elings Virgil B Apparatus and method for homogeneous immunoassay
US4594327A (en) 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4756828A (en) 1984-04-12 1988-07-12 Syntex (U.S.A.) Inc. Chromatographic strip having non-compressed edges
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4999285A (en) 1984-11-15 1991-03-12 Syntex (U.S.A.) Inc. Chromatographic cassette
US4624929A (en) 1984-12-03 1986-11-25 Syntex (U.S.A.) Inc. Sample collector and assay device and method for its use
DE3445816C1 (de) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flaechenfoermiges diagnostisches Mittel
US4803170A (en) 1985-05-09 1989-02-07 Ultra Diagnostics Corporation Competitive immunoassay method, device and test kit
US4623461A (en) 1985-05-31 1986-11-18 Murex Corporation Transverse flow diagnostic device
US4806311A (en) 1985-08-28 1989-02-21 Miles Inc. Multizone analytical element having labeled reagent concentration zone
US4868108A (en) 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
US4916056A (en) 1986-02-18 1990-04-10 Abbott Laboratories Solid-phase analytical device and method for using same
US5120504A (en) 1986-07-14 1992-06-09 Hybritech Incorporated Apparatus for immunoassays with vent chennels in the container side wall
US4963468A (en) 1986-09-05 1990-10-16 Syntex (U.S.A.) Inc. Immunoseparating strip
US4960691A (en) 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5030558A (en) 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US4770853A (en) 1986-12-03 1988-09-13 New Horizons Diagnostics Corporation Device for self contained solid phase immunodiffusion assay
US4920046A (en) 1987-02-20 1990-04-24 Becton, Dickinson And Company Process, test device, and test kit for a rapid assay having a visible readout
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
US4981786A (en) 1987-09-04 1991-01-01 Syntex (U.S.A.) Inc. Multiple port assay device
US4956302A (en) 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
US5006474A (en) 1987-12-16 1991-04-09 Disease Detection International Inc. Bi-directional lateral chromatographic test device
US5039607A (en) 1988-05-17 1991-08-13 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US5164294A (en) 1988-05-17 1992-11-17 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5079174A (en) 1988-12-08 1992-01-07 Boehringer Mannheim Corporation Apparatus for sequential determination of an analyte in a fluid sample
US5075078A (en) 1989-10-05 1991-12-24 Abbott Laboratories Self-performing immunochromatographic device
US5141850A (en) 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
ES2151902T3 (es) 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
US5356782A (en) 1992-09-03 1994-10-18 Boehringer Mannheim Corporation Analytical test apparatus with on board negative and positive control
US5753497A (en) 1995-12-22 1998-05-19 Universal Health Watch Inc Diagnostic assay providing blood separation
WO2002078512A2 (en) * 2001-04-02 2002-10-10 Therasense, Inc. Blood glucose tracking apparatus and methods
US20080112852A1 (en) * 2002-04-25 2008-05-15 Neel Gary T Test Strips and System for Measuring Analyte Levels in a Fluid Sample
US20050013809A1 (en) * 2002-12-02 2005-01-20 Owens Samuel M. Antibodies against drugs of abuse
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
EP2184607B1 (en) 2004-05-24 2012-07-11 Baylor Research Institute Immune response assessment method
US20100009389A1 (en) * 2008-07-14 2010-01-14 Masood Unnabi Khan Method of Making and Using Versatile Positive Controls and Antibody Detection Assays
AU2010303156B2 (en) * 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
US8655009B2 (en) * 2010-09-15 2014-02-18 Stephen L. Chen Method and apparatus for performing color-based reaction testing of biological materials
MX344053B (es) 2010-10-18 2016-12-02 Nestec Sa Metodos para determinar isotipos de anticuerpos anti-farmacos.
EP3105592B1 (en) * 2014-02-11 2018-10-17 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
US20150266758A1 (en) * 2014-03-18 2015-09-24 William R. Nelson Water treatment system
EP2982987A1 (en) * 2014-08-08 2016-02-10 Proteomika, S.L. Lateral flow immunoassays for the detection of antibodies against biological drugs

Also Published As

Publication number Publication date
AU2016246578A1 (en) 2017-11-16
US20160320405A1 (en) 2016-11-03
EP3280330A4 (en) 2019-01-09
WO2016164452A1 (en) 2016-10-13
US9927443B2 (en) 2018-03-27
EP3280330A1 (en) 2018-02-14
CA2982859A1 (en) 2016-10-13
CA2982859C (en) 2024-04-23

Similar Documents

Publication Publication Date Title
Samadder et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial
Carvajal et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial
Alloo et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma
BR112017004322A2 (pt) agentes de ligação ao cd123 e usos dos mesmos
BR112015028432A2 (pt) aparelho e método para administração de uma prescrição de dispositivo médico
Sayegh et al. Mirror therapy for Complex Regional Pain Syndrome (CRPS)—A literature review and an illustrative case report
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112018075300A2 (pt) métodos para tratamento do mal de alzheimer
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
Arnalich-Montiel et al. Successful monitoring and treatment of intraocular dissemination of Acanthamoeba
Pajaziti et al. Treatment of onychomycosis–A clinical study
BR112018074152A8 (pt) Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
BR112015022528A2 (pt) sistema e métodos para provar algaritmos de cuidados médicos a um usuário
BR112017021809A2 (pt) avaliação de riscos associados com fármacos terapêuticos
Sampson Alternating electric fields for the treatment of glioblastoma
Baumann et al. Assessing the validity of clinician advice that patients avoid use of topical agents before daily radiotherapy treatments
BR112019009495A2 (pt) métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
de Sire et al. Physical exercise with or without whole-body vibration in breast cancer patients suffering from aromatase inhibitor—Induced musculoskeletal symptoms: A pilot randomized clinical study
Davoodi et al. Effects of a self-care education program on quality of life of patients with gastric cancer after gastrectomy.
Mariyono et al. Adverse drug reaction
Scholl Complement Inhibition in Age-Related Macular Degeneration—Treat Early!
Berk et al. Randomized phase 2 trial of best supportive care: Manuka honey liquid and Manuka honey lozenges for prevention of radiation esophagitis during chemotherapy and radiation therapy for lung cancer
Vinolo-Gil et al. Blood Flow Restriction in Oncological Patients: Advantages and Safety Considerations
WO2019178379A3 (en) Precision medicine for pain: diagnostic biomarkers, pharmacogenomics, and repurposed drugs
Apelian et al. Person-Centred Dentistry: When Do We Start?

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2561 DE 04/02/2020.

B350 Update of information on the portal [chapter 15.35 patent gazette]